Next Treatments
Back to Eczema

soquelitinib

TypePill StagePhase 2 Latest updateFeb 24, 2026Phase 1 study completed

What stands out

New approach in eczema

  • Blocks ITK, a relay inside T cells that helps control their activation
Derived from NCT06345404 · UniProt Q08881 ·
11 US eczema labels (Cibinqo, Eucrisa, Adquey, Dupixent, Ebglyss, Nemluvio, Zoryve, Opzelura, Vtama, Adbry, Rinvoq)
· This is a summary of public records for informational purposes only. It is not medical advice.

History

Earliest recorded event: Apr 16, 2024. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Mar 2, 2026Phase 2 trial postedStudy to Evaluate Soquelitinib in Participants With Moderate to Severe AD ClinicalTrials.gov NCT07441395
  • Feb 24, 2026Phase 1 trial completedSafety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD ClinicalTrials.gov NCT06345404
  • Jan 28, 2026Phase 1 main data collectedSafety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD ClinicalTrials.gov NCT06345404
  • Apr 16, 2024Phase 1 trial startedSafety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD ClinicalTrials.gov NCT06345404

Sources

Trials